Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a commercial-stage healthcare technology company with a strong IP moat, highlighted by the recent issuance of a new US patent for pain assessment using MRS data. This supports the company's first-mover advantage in the chronic low back pain market, where it has a sizeable available market opportunity of over $400 million in the US alone. With a solid balance sheet of over $21 million in cash and a growing number of commercial agreements and clinical trials in progress, Aclarion's commercial momentum is expected to continue. Although the company's share count has increased, we maintain a positive outlook and have adjusted our 12-month price target to $7.50 to reflect these developments.

Bears say

Aclarion is a healthcare technology company with high operating expenses due to increased investments in sales, R&D, and IR. Potential risks to reaching share price targets include liquidity concerns, regulatory hurdles, and competition, as well as changes in consumer attitudes and macroeconomic factors. It receives a "neutral" rating from Ascendiant Capital Markets, LLC based on these factors.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.